Thrombosis Affecting Patents (Class 514/14.9)
  • Patent number: 10239933
    Abstract: Factor V peptides and methods of use thereof are disclosed.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: March 26, 2019
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Rodney M. Camire, Matthew W. Bunce, Mettine H. A. Bos
  • Patent number: 10060050
    Abstract: The present invention relates to the preparation of a compound library comprising the following steps: i. Having available at least two different compounds each comprising at least a dioxaborolane or dioxaborinane ring. In said compounds: the boron of the dioxaborolane or dioxaborinane ring is directly linked to a carbon atom of a hydrocarbon radical; at least one carbon atom of the dioxaborolane or dioxaborinane ring is monosubstituted, the other carbon atoms of the dioxaborolane or dioxaborinane ring being non-substituted or monosubstituted; in at least two compounds, the hydrocarbon radicals linked to the boron are different; in at least two compounds, the substituents carried by at least one of the carbon atoms of the dioxaborolane or dioxaborinane rings are different and/or the size of the boronic ester ring is different; ii. Reacting the compounds of step (i.) and forming, by a boronic ester metathesis reaction, the library comprising at least four different compounds.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: August 28, 2018
    Assignee: ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
    Inventors: Ludwik Leibler, Renaud Nicolay
  • Patent number: 9896480
    Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to ?5?1-Integrin, ?v?3-Integrin and ?v?5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: February 20, 2018
    Assignee: Allegro Pharmaceuticals, Inc.
    Inventors: Michael John Mackel, John Y. Park, Hampar L. Karageozian, Vicken H. Karageozian
  • Patent number: 9878018
    Abstract: The present invention relates to an injectable preparation comprising particles or fibrils with length less than 10 ?m and at least one pharmaceutically acceptable vehicle or excipient. The particles or fibrils comprise proteins or peptides inducing adhesion and activation of the platelets, or even aggregation thereof. The preparation is useful for treating hemorrhages.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: January 30, 2018
    Assignees: NVH Medicinal, Centre Hospitalier Universitaire De Dijon
    Inventors: David Vandroux, Laure Dumont, Emmanuel De Maistre
  • Patent number: 9522179
    Abstract: Embodiments herein report methods and compositions for treating cardiac conditions. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating a subject having or suspected of undergoing cardiac remodeling after a cardiac event. Other embodiments herein relate to compounds including naturally occurring and synthetic compositions of alpha-1 antitrypsin and fragments thereof.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: December 20, 2016
    Assignees: VIRGINIA COMMONWEALTH UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Charles A. Dinarello, Antonio Abbate, Eli C. Lewis
  • Patent number: 9457070
    Abstract: Embodiments of the present invention relate to compositions and methods for treatment of subjects in need of or having a bone marrow transplant. Certain embodiments describe compositions and methods for treatment of conditions associated with bone marrow transplantations in a subject, for example, Graft versus Host Disease (GvHD) or bone marrow transplantation rejection. Some embodiments concern early or immediate bone marrow transplantation rejection. Certain embodiments relate to compositions and uses of alpha1-antitrypsin (?1-antitrypsin, AAT) and carboxyterminal peptide derivatives thereof and/or compositions and uses of serine protease inhibitors, immunomodulators or anti-inflammatory agent activity similar to that of AAT.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: October 4, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Charles A. Dinarello, Eli C. Lewis
  • Patent number: 9085750
    Abstract: The conversion of a peptide aldehyde to a hydrosulfite adduct can be used to increase the aqueous solubility in the purification of the peptide aldehydes. Advantageously, this hydrosulfite adduct is itself effective as a subtilisin inhibitor and stabilizer and it can also stabilize a second enzyme if present. The hydrosulfite adduct is effective as a subtilisin inhibitor, and it maintains its inhibitory and stabilizing effect in a liquid detergent during storage. Thus, use of the hydrosulfite adduct can avoid the cost and time of converting it back to the peptide aldehyde and subsequent drying of the peptide aldehyde can be saved, and this can avoid the inconvenience of handling the peptide aldehyde in powder form or as a highly diluted aqueous solution.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: July 21, 2015
    Assignee: Novozymes A/S
    Inventors: Lise Munch Mikkelsen, Francesco Ponzini, Roberto Bisaccia, Renato Canevotti
  • Patent number: 9056118
    Abstract: An extract for preventing or treating thrombotic diseases, particularly, an extract of at least one of leeches and earthworms having a molecular weight of no more than 5,800 daltons is provided, wherein the extract includes 15% to 38% amino acid, 40% to 60% saccharide and 0.3% to 1% hypoxanthine. Processes for preparation, pharmaceutical compositions and uses thereof are also provided. Compared to conventional arts, the extract has safety greatly improved and drug actions maintained and even improved.
    Type: Grant
    Filed: June 17, 2012
    Date of Patent: June 16, 2015
    Assignee: Mudanjiang Youbo Pharmaceutical Co., LTD.
    Inventor: Zhenguo Li
  • Publication number: 20150147379
    Abstract: The embodiments relate generally to medical devices and to methods of their manufacture. One aspect provides devices including chitosan fibers that are a free of chemical cross linking. Another aspect provides a method of manufacturing such devices.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 28, 2015
    Applicant: COOK MEDICAL TECHNOLOGIES LLC
    Inventor: Mohammad Z. Albanna
  • Publication number: 20150105322
    Abstract: Methods for the expression and purification of non-N-glycosylated human Annexin A2 in yeast, e.g., in Pichia pastoris, purified Annexin A2 produced by those methods, and methods of using the Annexin A2.
    Type: Application
    Filed: October 11, 2012
    Publication date: April 16, 2015
    Inventor: Zhirui Wang
  • Publication number: 20150023975
    Abstract: Matrix metalloproteases (MMPs) play many important roles in normal and pathological remodeling processes including atherothrombotic disease, inflammation, angiogenesis and cancer. This invention relates to the activation of protease-activated receptor-1 (PAR-1) by endogenous platelet MMP-1 collagenase on the surface of platelets. Exposure of platelets to fibrillar collagen converts the surface-bound pro-MMP-1 zymogen to active MMP-1, which promotes aggregation through PAR-1. MMP-1 is shown to cleave the PAR-1 extracellular domain at a novel site, which then strongly activates Rho-GTP signaling pathways, cell shape change and motility, and MAPK signaling. Blockade of MMP-PAR1 suppresses thrombogenesis under arterial flow conditions and inhibited thrombosis in animals. These studies provide a link between matrix-dependent activation of metalloproteases and platelet-G protein signaling and identify MMP-1/PAR-1 as a new target for the treatment and prevention of arterial thrombosis and other thrombotic diseases.
    Type: Application
    Filed: August 14, 2014
    Publication date: January 22, 2015
    Inventors: Athan Kuliopulos, Georgios Koukos
  • Publication number: 20150005238
    Abstract: The present invention relates to the use of thrombomodulin analogues for the manufacture of a medicament for the treatment of coagulopathy with hyperfibrinolysis, such as haemophilia disorders. These thrombomodulin analogues exhibit at therapeutically effective dosages an antifibrinolytic effect. Novel protein modifications together with methods for their identification are disclosed.
    Type: Application
    Filed: December 15, 2010
    Publication date: January 1, 2015
    Applicant: Paion Deutschland GmbH
    Inventor: Daniel A. Nesheim
  • Publication number: 20140363423
    Abstract: The invention relates to a peptide compound and its pharmaceutical composition for inhibiting platelet aggregation and preventing/treating thrombogenic diseases. The invention develops pentapeptides and hexapeptides derived from snake venom C-type lectin-like proteins (CLPs) fragments, which can inhibit platelet aggregation and have antithrombotic activity without hemorrhagic tendency. Accordingly, they can be used as potential agents for the prevention and therapy of thrombogenic diseases.
    Type: Application
    Filed: June 14, 2012
    Publication date: December 11, 2014
    Inventors: Tur-Fu Huang, Chien-Hsin Chang, Ching-Hu Chung
  • Publication number: 20140364369
    Abstract: The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.
    Type: Application
    Filed: December 19, 2012
    Publication date: December 11, 2014
    Inventors: Hans-Peter Ekre, Anna Leitgeb, Mats Wahlgren, Dagmar Pikas
  • Publication number: 20140364368
    Abstract: The present invention provides stimulus responsive nanocomplexes comprising a masking moiety, e.g., a peptide, and a therapeutic moiety, e.g., an anti-coagulant. The invention also provides methods for treating or preventing a condition, such as a hypercoagulable state, e.g., blood clotting disorders or a cardiovascular disease, in a subject.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 11, 2014
    Inventors: Kevin Yu-ming Lin, Sangeeta N. Bhatia, Gabriel Abner Kwong, Justin Han-je Lo
  • Patent number: 8821871
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: September 2, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joanne Van Ryn, Keith Canada, Robert Copenhaver, Norbert Hauel, Tobias Litzenburger, Christopher Ronald Sarko, Sanjaya Singh, Alisa K. Waterman
  • Publication number: 20140228295
    Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.
    Type: Application
    Filed: February 10, 2014
    Publication date: August 14, 2014
    Applicant: The Board of Trustees of The University of Illinois
    Inventor: Xiaoping Du
  • Publication number: 20140221291
    Abstract: Factor V peptides and methods of use thereof are disclosed.
    Type: Application
    Filed: April 11, 2014
    Publication date: August 7, 2014
    Inventors: Rodney M. Camire, Matthew W. Bunce, Mettine H.A. Bos
  • Patent number: 8785387
    Abstract: The present invention relates to compositions and methods for preventing, treating or delaying various cardiovascular diseases or disorders in mammals, particularly in humans. More particularly, the present invention provides for compositions and methods for preventing, treating or delaying various cardiovascular diseases or disorders using, inter alia, a neuregulin protein, or a functional fragment thereof, or a nucleic acid encoding a neuregulin protein, or a functional fragment thereof, or an agent that enhances production and/or function of said neuregulin.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: July 22, 2014
    Assignee: Zensun (Shanghai) Science & Technology Limited
    Inventor: Mingdong Zhou
  • Patent number: 8758822
    Abstract: The present invention relates to a method for manufacturing uniform size polymeric nanoparticles containing poorly soluble drugs, and more particularly, to a method for manufacturing uniform size polymeric nanoparticles containing poorly soluble drugs, including a first step of dissolving a biodegradable polymer in a non-volatile polar organic solvent, a second step of adding poorly soluble drugs to water and the biodegradable polymer solution to produce a dispersion, and a third step of adding the dispersion to emulsifier solutions in a batch under the condition of low mechanical energy level stirring.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: June 24, 2014
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Bong Hyun Chung, Yong Taik Lim, Jung Hyun Han
  • Patent number: 8753631
    Abstract: The present invention is directed to a therapeutic agent comprising a GPIIIa(49-66) specific targeting agent and a thrombi-specific homing agent. Also disclosed is the use of the therapeutic agent in carrying out a method of treating thromboembolic disorders and a method of inducing platelet fragmentation.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: June 17, 2014
    Assignee: New York University
    Inventors: Simon Karpatkin, Michael Nardi, Zongdong Li
  • Publication number: 20140162955
    Abstract: The present disclosure provides combinations of salicylamide compounds, or pharmaceutically acceptable salts thereof, and histamine blocking agents, or pharmaceutically acceptable salts thereof, for antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative.
    Type: Application
    Filed: December 9, 2013
    Publication date: June 12, 2014
    Applicant: CELLCEUTIX CORPORATION
    Inventors: Richard W. Scott, Bozena Korczak, Nicholas Landekic
  • Patent number: 8741845
    Abstract: ClotBlock is a lyophilized fibrin hemostatic designed for use an adjunct or primary treatment in moderate to severe hemorrhage. It can be applied directly to the wound in a laparotomy procedure or as non-invasive sealant. Its crosslinking technology generates a strong and safe adhesive fibrin sealant required for high volume hemostasis. The attachment properties of the cake as well as the rapid formation of and stability of the fibrin clot ensures that a strong stable fibrin clot is formed within 1 to 5 minutes depending on the grade of the wound. The agent is safe, biocompatible, biodegradable and can be stored at room temperature for one year.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: June 3, 2014
    Assignee: Biomedica Mangement Corporation
    Inventors: George David Falus, Leonid Medved
  • Patent number: 8715672
    Abstract: The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and for preventing the formation and/or the stabilization of three dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: May 6, 2014
    Assignee: CSL Behring GmbH
    Inventors: Bernhard Nieswandt, Thomas Renne
  • Patent number: 8680052
    Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: March 25, 2014
    Assignee: The Medicines Company
    Inventors: Clive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats, David J. Schneider
  • Publication number: 20140066361
    Abstract: Peptides useful as angiotensin converting enzyme inhibitors are provided. Also provided are compositions comprising one or more of the peptides and methods for preventing, treating and/or diminishing one or more syndromes associated with angiotensin converting enzyme by using the peptides.
    Type: Application
    Filed: September 6, 2012
    Publication date: March 6, 2014
    Applicant: FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTE
    Inventors: YI-HONG CHEN, HSIANG-LING LAI, SHIAO-CHENG CHUANG, CHIEN-TI CHANG, MING-YU HUNG, YU-HUI LIU, SU-ER LIOU, FU-NING CHIEN, CHU-CHIN CHEN
  • Publication number: 20140051634
    Abstract: A pharmaceutical combined preparation containing a therapeutic protein having SH-groups which are nitrosated and a compound containing thiol groups and having an average molecular weight of at most 10,000.
    Type: Application
    Filed: August 15, 2013
    Publication date: February 20, 2014
    Applicant: AUSTRIA WIRTSCHAFTSSERVICE GESELLSCHAFT M.B.H.
    Inventors: Seth Hallström, Harald Gasser
  • Publication number: 20140044797
    Abstract: The present invention relates to the novel use of prostacyclin analogs for prevention and/or treatment of capillary leakage during surgery. The treatment of the present invention mediates discrete or minimal effects on haemostasis and vasodilation. Thus the present invention provides prostacyclin and analogs thereof for treatment which prevents capillary leakage while minimizing the risk of bleeding. The present invention further provides pharmaceutical compositions and kits of parts comprising prostacyclin or analogs thereof, and methods for treatment.
    Type: Application
    Filed: March 30, 2012
    Publication date: February 13, 2014
    Applicant: Rigshospitalet
    Inventors: Par Johansson, Sisse Rye Ostrowski
  • Patent number: 8647620
    Abstract: The present invention relates to chimeric Factor VII polypeptides and methods of using the same.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: February 11, 2014
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Darrel W. Stafford, Dengmin Feng
  • Publication number: 20140037614
    Abstract: The present invention provides a method for the prevention and/or reduction of peri- or postoperative complications following surgical intervention, such as complications following vascular surgery, especially peripheral vascular surgery, comprising administering a therapeutically effective amount of Annexin (A5) or a functional analogue or variant thereof to a patient in need of such treatment, Also provided is a pharmaceutical composition comprising a therapeutically effective amount of Annexin (A5) or a functional analogue or variant thereof for use in the prevention and/or reduction of peri- or postoperative complications following surgical intervention, such as complications following vascular surgery, especially peripheral vascular surgery.
    Type: Application
    Filed: April 5, 2012
    Publication date: February 6, 2014
    Inventor: Knut Pettersson
  • Patent number: 8633303
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: January 21, 2014
    Assignee: Glycomimetics, Inc.
    Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
  • Publication number: 20140011734
    Abstract: The present invention relates to compounds of the Formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, X1, X2, X3 and X4 have the meanings indicated in the claims, and which are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb), and are suitable, for example, for the therapy and prophylaxis of athero-thrombotic diseases. The invention furthermore relates to processes for the preparation of compounds of the Formula (I), their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: July 27, 2011
    Publication date: January 9, 2014
    Applicant: SANOFI
    Inventors: Otmar Klingler, Horst Blum, Andreas Lindenschmidt, Hans Matter
  • Patent number: 8623823
    Abstract: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.
    Type: Grant
    Filed: August 19, 2008
    Date of Patent: January 7, 2014
    Assignee: Midwestern University
    Inventor: Anil Gulati
  • Patent number: 8609693
    Abstract: The embodiments provide methods of administering a high dose or a loading dose of a TPO modulator to a subject. The embodiments further provide methods of treating thrombocytopenia and/or neutropenia in a subject. Additionally, the embodiments further provide methods of increasing platelet production and/or enhancing the number of peripheral blood stem cells in a subject.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: December 17, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Connie L. Erickson-Miller, Julian Jenkins
  • Patent number: 8603980
    Abstract: The present invention relates to methods and compositions for modulating platelet activity by inhibiting or activating glutamate receptors. The invention further relates to preventing or treating thrombotic diseases.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: December 10, 2013
    Assignee: The Johns Hopkins University
    Inventors: Craig N. Morrell, Charles J. Lowenstein
  • Publication number: 20130323264
    Abstract: The present application provides compositions and methods for modulating the activity and quantity of platelets and preventing and treating disorders or diseases associated with abnormal activity and quantity of platelets.
    Type: Application
    Filed: October 8, 2011
    Publication date: December 5, 2013
    Applicant: SHANGHAI KEXIN BIOTECH CO., LTD.
    Inventors: Yue Zhang, Jun Bao
  • Publication number: 20130316951
    Abstract: The present invention relates to: a composition for dissolving thrombi comprising a peptide comprising the Arg-Gly-Asp motif; a pharmaceutical composition for treating stenotic or occlusive vascular diseases which comprises the same; and a thrombus dissolving method and a method for treating stenotic or occlusive vascular diseases, comprising the step of administering the same. The compositions and methods of the present invention have the advantage that they effectively break down already formed thrombi by adopting the principle of targeting integrin within the thrombus such as platelet surface GPIIb-IIIa, which is not the same as the existing principle of plasminogen activation. Also, the compositions and methods of the present invention have a nerve-protecting function as they effectively open as far as the microvasculature, without the occurrence of restenosis after penetration.
    Type: Application
    Filed: November 1, 2011
    Publication date: November 28, 2013
    Inventors: Ji Hoe Heo, Il Kwon, Young Dae Kim, Sung Yu Hong
  • Publication number: 20130315897
    Abstract: The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.
    Type: Application
    Filed: May 8, 2013
    Publication date: November 28, 2013
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Stanley J. Hollenbach, Patrick Andre
  • Patent number: 8586711
    Abstract: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: November 19, 2013
    Assignee: Nektar Therapeutics
    Inventors: Mary J. Bossard, Gayle Stephenson
  • Patent number: 8568724
    Abstract: The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor XI and that inhibit factor XI activation and/or activity. The factor XI-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor XI activation and/or wherein inhibition of factor XI has a beneficial effect.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: October 29, 2013
    Inventor: Erik Hack
  • Patent number: 8569237
    Abstract: The present invention relates to a chimeric hirudin protein comprising a carrier attached to the N-terminus of hirudin, with an intervening plasmin cleavage site. The chimeric hirudin protein contains a relatively inactive form of hirudin. However, when such chimeric hirudin protein being cleaved by plasmin in the vicinity of a clot and, ultimately causing the release of active hirudin and the reduction of the size of the clot. The chimeric hirudin protein exhibited much slower clearance in mice than unfused wild-type hirudin.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: October 29, 2013
    Assignee: Canadian Blood Services, Inc.
    Inventor: William P. Sheffield
  • Publication number: 20130274195
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Application
    Filed: December 24, 2012
    Publication date: October 17, 2013
    Inventors: CELERA CORPORATION, LEIDEN UNIVERSITY MEDICAL CENTER (LUMC) Acting on Behalf of ACADEMIC HOSPITAL LEIDEN
  • Patent number: 8541370
    Abstract: The present invention relates to the use of matrix metalloproteinase MMP-10 in the preparation of a pharmaceutical composition useful for thrombolytic therapy, it also being possible for said composition to contain a plasminogen activator. Additionally, the present invention relates to said pharmaceutical composition for the treatment of thrombotic disorders.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: September 24, 2013
    Assignee: Proyecto de Biomedicina Cima, S.L.
    Inventors: Josune Orbe Lopategui, Jose Antonio Rodriguez Garcia, Jose Antonio Paramo Fernandez, Rosario Serrano Vargas
  • Publication number: 20130236441
    Abstract: A method of treating or preventing a thrombotic disease in a subject in need thereof comprises administering to the subject an effective amount of a pharmaceutical composition comprising an inhibitor of an apoptosis signal regulating kinase 1 (ASK1) protein. A method of identifying an inhibitor of an apoptosis signal regulating kinase 1 (ASK1) protein useful for treating or preventing a thrombotic disease, comprising (a) contacting a candidate agent with a test sample comprising the ASK1 protein, and (b) comparing the ASK1 protein activity in the test sample with the ASK1 protein activity in a control sample that has not been contacted with the candidate agent, whereby a decrease in the ASK1 protein activity in the test sample compared with the control sample indicates that the candidate agent is an ASK1 inhibitor.
    Type: Application
    Filed: November 18, 2011
    Publication date: September 12, 2013
    Applicant: University of Delaware
    Inventors: Ulhas P. Naik, Meghna U. Naik
  • Patent number: 8507436
    Abstract: The present invention relates to isolated 18-mer peptides corresponding to amino acid residues 369-386 of human plasminogen activator inhibitor 1 (PAI-1) and fragments thereof, compositions that include such peptides, and uses of such compositions for treating thromboembolic diseases and pathological conditions associated with neurological damage.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: August 13, 2013
    Assignee: D-Pharm Ltd.
    Inventor: Abd Al-Roof Higazi
  • Publication number: 20130195837
    Abstract: This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31).
    Type: Application
    Filed: December 30, 2010
    Publication date: August 1, 2013
    Inventors: Kenneth Borow, D. Travis Wilson
  • Publication number: 20130172233
    Abstract: An extract for preventing or treating thrombotic diseases, particularly, an extract of at least one of leeches and earthworms having a molecular weight of no more than 5,800 daltons is provided, wherein the extract includes 15% to 38% amino acid, 40% to 60% saccharide and 0.3% to 1% hypoxanthine. Processes for preparation, pharmaceutical compositions and uses thereof are also provided. Compared to conventional arts, the extract has safety greatly improved and drug actions maintained and even improved.
    Type: Application
    Filed: June 17, 2012
    Publication date: July 4, 2013
    Inventor: Zhenguo Li
  • Patent number: 8476249
    Abstract: Invented is a method of treating thrombocytopenia in a human, in need thereof which comprises the in vivo administration of a therapeutically effective amount of a peptide or a non-peptide TPO receptor agonist and an anti-clotting agent or agents, and optional further active ingredients, to such human.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: July 2, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Connie L. Erickson-Miller, Michael Arning
  • Patent number: 8466108
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: June 18, 2013
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
  • Patent number: 8455440
    Abstract: The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: June 4, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Stanley J. Hollenbach, Patrick Andre